Use access key #2 to skip to page content.
$44.13 0.23 (0.52%)
5/12/2008 4:00 PM

GlaxoSmithKline plc (ADR) (GSK)

CAPS Rating:
****

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating GSK

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

773 Outperforms
52 Underperforms
 

All-Stars

231 Outperforms
17 Underperforms
 

Wall Street

7 Outperforms
3 Underperforms
 

Players bullish on GSK are also bullish on:

Players bearish on GSK are also bearish on:

Ticker Tags

Behemoth (33), Buffett Stock (50), United Kingdom (47), Dividend (184), Mega Cap (146), Big Pharma (12), Drug Manufacturers - Major (27), Multinational Company (16), Bird Flu (8), Optionable (32)
Suggest a tag

GlaxoSmithKline plc (ADR) At A Glance

Current Price: $44.13
Last Trade Time: 5/12/2008 4:00 PM
Open: $44.24
Previous Close: $43.90
Daily Range: $43.87 - $44.25
52-Week Range: $40.51 - $58.15
Volume: 723,967
Market Cap: $117.89B
P/E Ratio: 15.03
Compare Our Special Broker Offers!

Stock Trends

GSK VS S&P 500 (SPY)

GSK 12 month chart vs. S&P

News & Discussion Boards

Top Bull Pitch

Recs

1

GlaxoSmithKline plc (ADR) (GSK)

Avatar xthecritic (69.20) Submitted: 4/23/08 8:56 AM

Ask CAPS to stop censoring user blogs.

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 152 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (GSK)

Avatar BlindSkuirrel (41.37) Submitted: 5/08/08 6:19 PM : Underperform Start Price: $43.99 GSK Score: 1.17

Rectum refuse - mgmt sucks!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GSK)

Avatar lntwo (86.86) Submitted: 5/07/08 2:06 AM : Outperform Start Price: $44.07 GSK Score: 1.19

Waiting for the buy out of my Sirtris shares (yessss!) and figured I'd follow the money, so to speak. Sirtris will be releasing novel chemical entity data in the next 3 months that should confirm safety and function. WB dimension doesn't hurt either.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GSK)

Avatar Tankota (98.38) Submitted: 5/06/08 8:37 AM : Underperform Start Price: $44.58 GSK Score: 1.27

TJC

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GSK)

Avatar colonelnelson (47.64) Submitted: 4/30/08 11:29 PM : Outperform Start Price: $44.51 GSK Score: -2.01

Great value at this price, GSK is much better diversified than many other pharmaceutical companies because of their separate drug and consumer healthcare divisions.





The ratios look right at this price, the financials look strong and this company seems like quite the bargain for so profitable an outlook.





I'm going long.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GSK)

Avatar kahunacfa (< 20) Submitted: 4/29/08 11:29 AM : Outperform Start Price: $43.85 GSK Score: -0.41

GlaxoSmithKline, plc is an undervalued major pharmaceutucal company in my opinion. The stock is currently selling near $44.25 per share and has an Intrinsic Value of approximately $74 - $76 per share by my model.





GSK is a BUY at $44.25 with a price objective of $75 in three to five years.





Kahuna,CFA

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 152 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 10 of 10  

picks per page. CHANGE Expand All Pitches

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackJimCramer 81.00 05/05/08 Underperform 3W $44.89-1.69%-0.26%+1.43
TrackUBS 93.95 02/11/08 Outperform NS $41.75+5.71%+5.53%+0.18
TrackJohnKeeley 94.97 09/30/07 Outperform NS $51.31-13.99%-7.94%-6.04 Toggle the visibility of 60-Second Pitch and replies
TrackDodgeCox 93.10 09/30/07 Outperform NS $51.31-13.99%-7.94%-6.04 Toggle the visibility of 60-Second Pitch and replies
TrackSnow 81.11 09/30/07 Outperform NS $51.31-13.99%-7.94%-6.04 Toggle the visibility of 60-Second Pitch and replies
TrackNWQ 29.20 09/30/07 Outperform NS $51.31-13.99%-7.94%-6.04 Toggle the visibility of 60-Second Pitch and replies
TrackBrandes < 20 09/30/07 Outperform NS $51.31-13.99%-7.94%-6.04 Toggle the visibility of 60-Second Pitch and replies
TrackEdwardOwens 71.22 09/30/07 Outperform NS $51.31-13.99%-7.94%-6.04 Toggle the visibility of 60-Second Pitch and replies
TrackBearStearns 93.79 07/25/07 Underperform NS $50.82-13.17%-7.60%+5.56
TrackJPMorgan 90.32 03/22/07 Underperform NS $52.61-16.12%-2.10%+14.02

Results 1 - 10 of 10  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners